Leerink Partners analyst Andrew Berens has maintained their neutral stance on BPMC stock, giving a Hold rating on February 14.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Berens has given his Hold rating due to a combination of factors surrounding Blueprint Medicines’ recent financial performance and future projections. The company reported its fourth-quarter earnings for 2024 and provided guidance for Ayvakit revenue in 2025, which, although within the expected range, fell short of Berens’s estimates and investor expectations. This discrepancy resulted in a decrease in the stock price.
Furthermore, the forecast for Ayvakit sales in 2025 suggests a potential slowdown in the addition of new US iSM patients, with management pointing out several influencing factors, including compliance rates and insurance reverification processes. Additionally, the company’s increased operating expenses to support new investments and the removal of contributions from a deprioritized program also influenced the Hold rating. These considerations led to a decrease in the price target, reflecting cautious optimism about the company’s future performance.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Exelixis, and Incyte. According to TipRanks, Berens has an average return of -7.0% and a 36.78% success rate on recommended stocks.
In another report released on February 14, Morgan Stanley also maintained a Hold rating on the stock with a $120.00 price target.